Lúpus eritematoso sistêmico e sua associação com proteína quimioatraente de monócitos 1 (MCP1) e interleucina 6

Abstract

INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by abnormalities in T and B lymphocytes that will lead to loss of tolerance to nuclear autoantigens and the production of autoantibodies that cause inflammation and damage to multiple organs and systems. An increasing variety of abnormalities in cytokines and chemokines has been implicated both in their pathogenesis and in secondary markers that reflect the present immune dysregulation. Due to its immunological and clinical complexity, with varied phenotypic presentations, diagnosis and prognostic evaluation are often not easy, but always necessary, for a correct approach and to avoid the damage resulting from the disease. Thus, the present study aims to associate serum (s) interleukin 6 (IL-6) and serum and urinary (u) chemoattracting protein of monocytes 1(MCP-1) in SLE, seeking ways to assist in the diagnosis and prognostic evaluation. METHODS: In this sense, a case-control study involving 65 SLE patients treated at the University Hospital prof. Alberto Antunes, and 50 controls matched for age and education. Clinical parameters were evaluated in the patient group, and IL-6, sMCP-1 and uMCP-1 were measured for patients and controls. RESULTS: SLE patients had higher values for all biomarkers compared to the control group, but there were no significant differences in the group of patients regarding the association with disease activity (by SLEDAI ≥ 4), consumption of serum supplements, nephritis in activity or proteinuria, showing the importance of these markers in the diagnosis, but perhaps without a prognostic or evaluation relation to the treatment. CONCLUSION: sMCP-1 can be na important biomarker to assist in the diagnosis of SLE, and its positive correlation with IL-6 brings more specificity and importance for its use in clinical practice, since the increase in IL-6 is already well documented in literature. New studies combining biomarkers are necessary, and of great use for the diagnosis and monitoring of the course of SLE.